These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 11747386)

  • 1. Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension.
    Furberg CD; Psaty BM; Pahor M; Alderman MH
    Ann Intern Med; 2001 Dec; 135(12):1074-8. PubMed ID: 11747386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2015 Feb; 33(2):195-211. PubMed ID: 25485720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
    Davis BR; Cutler JA; Gordon DJ; Furberg CD; Wright JT; Cushman WC; Grimm RH; LaRosa J; Whelton PK; Perry HM; Alderman MH; Ford CE; Oparil S; Francis C; Proschan M; Pressel S; Black HR; Hawkins CM
    Am J Hypertens; 1996 Apr; 9(4 Pt 1):342-60. PubMed ID: 8722437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental approaches to determining the choice of first-step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Whelton PK; Williamson JD; Louis GT; Davis BR; Cutler JA
    Clin Exp Hypertens; 1996; 18(3-4):569-79. PubMed ID: 8743044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.
    Ettehad D; Emdin CA; Kiran A; Anderson SG; Callender T; Emberson J; Chalmers J; Rodgers A; Rahimi K
    Lancet; 2016 Mar; 387(10022):957-967. PubMed ID: 26724178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M;
    Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
    Düsing R
    Dtsch Med Wochenschr; 2003 Jan; 128(5):214-6. PubMed ID: 12557115
    [No Abstract]   [Full Text] [Related]  

  • 11. Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Dhruva SS; Huang C; Spatz ES; Coppi AC; Warner F; Li SX; Lin H; Xu X; Furberg CD; Davis BR; Pressel SL; Coifman RR; Krumholz HM
    Hypertension; 2017 Jul; 70(1):94-102. PubMed ID: 28559399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What ALLHAT tells us about treating high-risk patients with hypertension and hyperlipidemia.
    Geraci TS; Geraci SA
    J Cardiovasc Nurs; 2003; 18(5):389-95. PubMed ID: 14680343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
    Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the management of hypertension: recent clinical trials and the JNC 7.
    Moser M
    J Clin Hypertens (Greenwich); 2004 Oct; 6(10 Suppl 2):4-13. PubMed ID: 15470293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial.
    Davis BR; Cutler JA; Furberg CD; Wright JT; Farber MA; Felicetta JV; Stokes JD;
    Ann Intern Med; 2002 Sep; 137(5 Part 1):313-20. PubMed ID: 12204014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
    Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cochrane in context: pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
    Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: results from major clinical trials.
    Black HR
    Clin Cornerstone; 2004; 6(4):53-66. PubMed ID: 15850766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The ALLHAT study (antihypertensive and lipid-lowering treatment to prevent heart attack trial): primary antihypertensive agents - diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors].
    Scholze J; Unger T
    Internist (Berl); 2003 Sep; 44(9):1193-5. PubMed ID: 14566471
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.